As part of the Japanese firm's reorganisation of its research & development structure
Daiichi Sankyo is closing its U3 Pharma research unit in Germany as it consolidates its global R&D capacity.
U3 Pharma, based in Martinsried, employs around 40 people in research and development work on antibody targeting for cancer treatments.
The Japanese firm will transfer the group's work to its biologics research unit in Tokyo, the company said.
Daiichi Sankyo said it will provide a more detailed update on the impact of this move in its business results for 2015 at a later date.